Advaxis, Inc. Completes Pre-IND Meeting for ADXS-PSA

Published: Aug 11, 2011

PRINCETON, N.J--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed a pre-IND (Investigational New Drug) meeting with the FDA on August 10 to discuss the development plan for ADXS-PSA, a construct for the treatment of prostate cancer. The FDA addressed the company’s questions and provided guidance on the requirements to file an IND to initiate clinical trials. This IND is expected to be filed before the end of the year.

Back to news